Literature DB >> 26412481

Epidemiology of bloodstream infections caused by methicillin-resistant Staphylococcus aureus at a tertiary care hospital in New York.

Mohamad Yasmin1, Halim El Hage2, Rita Obeid3, Hanine El Haddad2, Mazen Zaarour2, Ambreen Khalil2.   

Abstract

BACKGROUND: In the United States, bloodstream infections (BSIs) are predominated by Staphylococcus aureus. The proportion of community-acquired methicillin-resistant S aureus (MRSA) BSI is on the rise. The goal of this study is to explore the epidemiology of BSI caused by S aureus within Staten Island, New York.
METHODS: This is a case-case-control study from April 2012-October 2014. Cases were comprised of patients with BSI secondary to MRSA and methicillin-sensitive S aureus (MSSA). The control group contained patients who were hospitalized during the same time period as cases but did not develop infections during their stay. Two multivariable models compared each group of cases with the uninfected controls.
RESULTS: A total of 354 patients were analyzed. Infections were community acquired in 76% of cases. The major source of BSI was skin-related infections (n = 76). The first multivariable model showed that recent central venous catheter placement was an independent infection risk factor (odds ratio [OR] = 80.7; 95% confidence interval [CI], 2.2-3,014.1). In the second model, prior hospital stay >3 days (OR = 4.1; 95% CI, 1.5-5.7) and chronic kidney disease (OR = 3.0; 95% CI, 1.01-9.2) were uniquely associated with MSSA. Persistent bacteremia, recurrence, and other hospital-acquired infections were more likely with MRSA BSI than MSSA BSI.
CONCLUSION: Most infections were community acquired. The presence of a central venous catheter constituted a robust independent risk factor for MRSA BSI. Patients with MRSA BSI suffered worse outcomes than those with MSSA BSI.
Copyright © 2016 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antibiotic resistance; MRSA; Methicillin-resistant Staphylococcus aureus; New York; Risk factors; Staphylococcus

Mesh:

Year:  2015        PMID: 26412481     DOI: 10.1016/j.ajic.2015.08.005

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  5 in total

Review 1.  Association between high vancomycin minimum inhibitory concentration and clinical outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: a meta-analysis.

Authors:  Hassan Ishaq; Wajeeha Tariq; Khawaja Muhammad Talha; Bharath Raj Varatharaj Palraj; M Rizwan Sohail; Larry M Baddour; Maryam Mahmood
Journal:  Infection       Date:  2021-01-04       Impact factor: 3.553

2.  Is the Success of Cefazolin plus Ertapenem in Methicillin-Susceptible Staphylococcus aureus Bacteremia Based on Release of Interleukin-1 Beta?

Authors:  Dan Smelter; Mary Hayney; George Sakoulas; Warren Rose
Journal:  Antimicrob Agents Chemother       Date:  2022-01-03       Impact factor: 5.938

3.  Drug-resistance dynamics of Staphylococcus aureus between 2008 and 2014 at a tertiary teaching hospital, Jiangxi Province, China.

Authors:  Kaisen Chen; Yanfang Huang; Qiuyue Song; Chenhui Wu; Xiaowen Chen; Lingbing Zeng
Journal:  BMC Infect Dis       Date:  2017-01-25       Impact factor: 3.090

4.  Epidemiology of Community-Onset Staphylococcus aureus Bacteremia.

Authors:  James Y Yarovoy; Andrew A Monte; Bryan C Knepper; Heather L Young
Journal:  West J Emerg Med       Date:  2019-04-16

5.  Staphylococcal Enterotoxins and Toxic Shock Syndrome Toxin-1 and Their Association among Bacteremic and Infective Endocarditis Patients in Egypt.

Authors:  Heba M Elsherif; Zeinab H Helal; Mona R El-Ansary; Zeinab A Fahmy; Wafaa N Eltayeb; Sahar Radwan; Khaled M Aboshanab
Journal:  Biomed Res Int       Date:  2020-12-18       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.